NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with ...

NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, ...

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic Lymphatic Malformations in U.S.; significant commercial opportunity based on an estimated more ...

Enrollment in additional cohorts underway with initial results expected in 1H’25 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (TARA), a clinical-stage company developing ...

80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical success Clinical success achieved with one or two doses of TARA-002 in ...

NEW YORK - Protara Therapeutics, Inc. (NASDAQ:TARA) announced positive interim results from its Phase 2 STARBORN-1 trial evaluating TARA-002 for pediatric patients with lymphatic malformations (LMs).

Company remains on track to report top line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of microcystic LMs, in Q1 2026 QTORIN™ ...

Kennedy Hubbard looks different than most 20-somethings. “We’re well aware of how she appears,” Kennedy’s mom, Leanne, said. “It’s human nature to stare. It’s just not something you see all the time.

Earnings call Palvella ended Q3 2025 with $63.6M in cash, supporting operations into H2 2027. The SELVA Phase 3 trial for Qutoran rapamycin in microcystic lymphatic malformations remains on track for ...